A5013814515- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
- Virus-based gene therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- Galectins and Cancer Biology
- RNA Research and Splicing
- Immunotherapy and Immune Responses
- Phagocytosis and Immune Regulation
- Cancer-related Molecular Pathways
- Neutropenia and Cancer Infections
- Wnt/β-catenin signaling in development and cancer
- PI3K/AKT/mTOR signaling in cancer
- RNA modifications and cancer
- Multiple Myeloma Research and Treatments
- RNA Interference and Gene Delivery
Mayo Clinic in Florida
2018-2025
Mayo Clinic in Arizona
2018-2025
University of California, San Diego
2011-2024
WinnMed
2019-2024
Mayo Clinic Hospital
2018-2024
Phoenix (United States)
2022-2023
King Faisal Specialist Hospital & Research Centre
2023
Clinical Research Consortium
2004-2022
University of California System
2022
Moores Cancer Center
2008-2019
In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.In this multicenter, 2 we enrolled 111 diffuse lymphoma, primary mediastinal or transformed follicular who had disease despite undergoing recommended prior therapy. Patients received target dose 2×106 CAR T cells per kilogram body weight receiving conditioning...
Salinomycin, an antibiotic potassium ionophore, has been reported recently to act as a selective breast cancer stem cell inhibitor, but the biochemical basis for its anticancer effects is not clear. The Wnt/β-catenin signal transduction pathway plays central role in development, and aberrant activation can cause cancer. In this study, we identified salinomycin potent inhibitor of Wnt signaling cascade. Wnt-transfected HEK293 cells, blocked phosphorylation coreceptor lipoprotein receptor...
We examined the sera of six patients before and after i.v. infusions autologous chronic lymphocytic leukemia (CLL) cells transduced ex vivo with an adenovirus encoding CD154 (Ad-CD154). Five made high-titer antibodies against three IgG reactive a leukemia-associated surface antigen, which we identified as ROR1. Anti-ROR1 were not detected in untreated patients. generated anti-ROR1 mAbs found they reacted specifically CLL all patients, but nonleukemic leukocytes, wide variety normal adult...
Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification patients and development newer treatment options. Identification ALL subtypes based on immunophenotyping cytogenetic molecular markers has resulted in inclusion Philadelphia-like early T-cell precursor that affect prognosis. Ikaros mutations also emerged a prognostic factor. In addition prognostication, options for with have expanded, particularly regard relapsed/refractory...
RNA splicing plays a fundamental role in human biology. Its relevance cancer is rapidly emerging as demonstrated by spliceosome mutations that determine the prognosis of patients with hematologic malignancies. We report studies using FD-895 and pladienolide-B primary leukemia cells derived from chronic lymphocytic leukemia-lymphoma cell lines. found induce an early pattern mRNA intron retention - modulation. This process was associated apoptosis preferentially compared to normal lymphocytes....
// Manoj K. Kashyap 1 , Deepak Kumar Harrison Jones Carlos I. Amaya-Chanaga Michael Y. Choi Johanna Melo-Cardenas Amine Ale-Ali Michelle R. Kuhne 3 Peter Sabbatini 4 Lewis J. Cohen Suresh G. Shelat Laura Z. Rassenti 2 Thomas Kipps 1,2 Pina M. Cardarelli and Januario E. Castro UCSD-Moores Cancer Center, La Jolla, CA, USA CLL Research Consortium, Bristol-Myers Squibb, Department of Cell Biology Physiology, Redwood City, Early Clinical Translational Research, Princeton, NJ, Correspondence to:...
Purpose Lenalidomide is an immunomodulatory agent with therapeutic activity in chronic lymphocytic leukemia (CLL). In preclinical models, lenalidomide acted synergistically rituximab. The CLL Research Consortium initiated a phase II study to evaluate this combination treatment-naive patients. Patients and Methods was at 2.5 mg/day escalated based on treatment tolerability maximum of 10 mg/day, for 21 days/cycle, seven cycles. Rituximab administered the end cycle 1 continued received...
The CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported different hematological malignancies including CLL. Binding pro-survival chemokine CXCL12 with its cognate receptor induces cell migration. CXCL12/CXCR4 signaling promotes survival and proliferation may contribute to tropism cells towards lymphoid tissues bone marrow. Therefore, we hypothesized that targeting IgG1 antibody,...
Chimeric Antigen Receptor (CAR) T-cell therapies have emerged as an effective and potentially curative immunotherapy for patients with relapsed or refractory malignancies. Treatment CD19 CAR T-cells has shown unprecedented results in hematological malignancies, including heavily leukemia, lymphoma, myeloma cases. Despite these encouraging results, therapy faces limitations, the lack of long-term responses nearly 50-70% treated low efficacy solid tumors. Among other reasons, restrictions are...
BIIB021 is the first oral, synthetic, non-geldanamycin-based HSP90 inhibitor that showed activity in preclinical models at low nanomolar concentrations. We performed a phase 1 trial of administered to subjects with advanced solid tumors.Sixty patients received capsules orally on days 1, 4, 8, 11, 15, and 18 each course schedule 18, 22, 25 2. The treatment schedules were repeated every 28 days. In addition determining MTD, we evaluated pharmacokinetics pharmacodynamic effects [Hsp70, HER2...
Chronic lymphocytic leukemia (CLL) is the most common lymphoid neoplasia in Western societies and currently incurable. Multiple treatment options are practiced, but available small molecule drugs suffer from dose-limiting toxicity undesirable side effects. The need for new, less toxic treatments a pressing concern. Here, we demonstrate that (-)-agelastatin A (1a), pyrrole-imidazole alkaloid obtained marine sponge, exhibits potent vitro activity against primary cell lines of CLL disclose...